Covid-19 News

  • Are COVID-19 Vaccines Adversely Impacting Women’s Menstrual Cycles?


    Are COVID-19 Vaccines Adversely Impacting Women’s Menstrual Cycles?
    Are COVID-19 vaccines impacting female menstrual cycles? A new Israeli study seeks to find out as mounting real-world data points to a phenomenon observed
    trialsitenews.com


    Are COVID-19 Vaccines Adversely Impacting Women’s Menstrual Cycles?


    Are COVID-19 vaccines impacting female menstrual cycles? A new Israeli study seeks to find out as mounting real-world data points to a phenomenon observed in women worldwide after receiving the second vaccine dose. Social media in Israel was recently abuzz with women sharing their experiences, ranging from irregularity to unusual amounts of bleeding. In other cases, postmenopausal women report bleeding. At the same time, medical establishment experts cannot explain the observations or even link such a phenomenon to the jabs, perhaps in part because these observations could be associated with any number of other causes. Regardless of the ever-growing number of complaints after vaccination, clinical investigators are moving to study the situation in more detail. For example, the American government has put $1.76 million to study the subject in a study led by Johns Hopkins University’s Mostafa Borahay, MD, Ph.D., associate professor of gynecology and obstetrics at Johns Hopkins University School of Medicine. While in Israel, chairman of the Israel Society of Obstetrics and Gynecology, Professor Roni Maimon of Shamir Medical Center, initiates Israel’s first investigation into the matter.


    The Subject

    Known as Menstruation or more casually as a period, this event is part of a woman’s monthly reproductive cycle. Every month, a woman’s uterus prepares for pregnancy and thickens its walls by increasing the levels of two hormones, estrogen and progesterone. If pregnancy fails to occur, the uterus sheds its lining as the blood and mucus make up the menstrual flow that leaves the body through the vagina during the period.


    The Israeli Situation

    One of the most vaccinated places on the planet against COVID-19, Israel has become sort of a real-world laboratory for issues associated with COVID-19 vaccination.


    Recently, Haaretz’ Ido Efrati reported that some vaccinated Israeli women were reporting irregular menstrual cycles. While there is no proof the issues originate from the vaccine, the irregularities are spooking vaccinated females concerned about associated fertility issues.


    Back to America

    In the U.S., Johns Hopkins Medicine’s Department of Gynecology and Obstetrics is one of five selected study centers to investigate the impacts of COVID-19 vaccines on Menstruation.


    The aforementioned $1.67 million grant funded by the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development as well as the NIH Office of Research on Women’s Health is led by Mostafa Borahay, MD, Ph.D., associate professor of gynecology and obstetrics at Johns Hopkins University School of Medicine.


    According to a recent quote from Professor Borahay, “There may be several reasons why a woman might experience unscheduled menstrual bleeding, abnormal periods or bleeding that is heavier than usual.” The Johns Hopkins investigator continued, “This research will help us better understand if there’s a real link between the COVID-19 vaccines and these menstrual changes, or if there is something else, such as lifestyle changes or pandemic-related stress.”


    Possible Hypothesis

    According to the Johns Hopkins team, the possible explanation associates with the vaccinated person’s immune response post-vaccination. That is, the jab may bring immune cells into the endometrium (uterus). This could possibly lead to observations occurring around the world.


    Professor Borahay continued, “If there’s a relationship between the COVID-19 vaccines and the menstrual changes, we need to know how it happens.” And the doctor emphasized, “Therefore, we plan to examine the response of the endometrium to the COVID-19 vaccination at the biological level.”


    Observational Study in the UK

    One recent study out of the UK led to inconclusive results. Published in the BMJ, the Imperial College School of Medicine and Westminster Hospital investigators studied over 30,000 reports of irregular menstrual symptoms during a period associated with COVID-19 vaccination until September 2, 2021.


    The subjects in this observational study report that the conditions had seemingly gone back to normal by their next cycle. TrialSite reported recently that the lead investigator, Dr. Victoria Male, suggests further research be conducted.


    Lead Research/Investigator

    Mostafa Borahay, MD, Ph.D., associate professor of gynecology and obstetrics at Johns Hopkins University School of Medicine


    Professor Roni Maimon of Shamir Medical Center


    Call to Action: TrialSite will monitor this research and provide updates as they are available.


    Menstrual changes after covid-19 vaccination
    A link is plausible and should be investigated Common side effects of covid-19 vaccination listed by the UK’s Medicines and Healthcare Products Regulatory…
    www.bmj.com

  • Antibodies last over a year after COVID-19 infection, according to study

    Those who experienced severe infection had higher levels of antibodies.


    Antibodies last over a year after COVID-19 infection, according to study
    Those who experienced severe infection had higher levels of antibodies.
    justthenews.com


    Most people who have been infected with SARS-CoV-2, the virus that causes COVID-19, will carry antibodies for at least a year, according to a recent peer-reviewed study

    The European Journal of Immunology accepted a study on Sept. 24 from scientists at the Finnish Institute for Health and Welfare, who studied 1,292 subjects eight months after infection for the presence of antibodies.


    Their findings included 96% of subjects still carrying neutralizing antibodies and 66% with the nucleoprotein IgG antibody.


    After randomly selecting 367 subjects from the original cohort who were not yet vaccinated a year following infection, the scientists found that 89% of subjects still had neutralizing antibodies, and 36% with the IgG antibody.


    Subjects who had experienced a severe SARS-CoV-2 infection had higher antibody levels, anywhere from two to seven times as many antibodies as those with mild infections at least 13 months after contracting the disease.


    While the antibodies provide lasting protection against the original SARS-CoV-2 virus, their neutralization efficiency against the Alpha, Beta, and Delta variants decreased over time.


    The neutralizing antibodies "were only slightly reduced" in the Alpha variant and "considerably declined" in the Beta variant. However, "over 80% of the subjects who had recovered from severe" SARS-CoV-2 infection still had neutralizing antibodies against the Delta variant a year after being infected.


    Nature Medicine published a study in May that found "that neutralization level is highly predictive of immune protection" against SARS-CoV-2.


    A preliminary study, which is not yet peer-reviewed, found that antibodies decreased 10-fold just seven months after subjects received the second dose of the Pfizer COVID-19 vaccine


    Error - Cookies Turned Off


    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection - Nature Medicine
    Estimates of the levels of neutralizing antibodies necessary for protection against symptomatic SARS-CoV-2 or severe COVID-19 are a fraction of the mean level…
    www.nature.com

  • CDC guidance says to use a cycle threshold (CT) of 40,

    Everything above 32 is false positive or non infective at least.... These folks are criminals!

    Also the pill for 700 kilos of horse would be almost the size of a golf ball.

    NO: You get 8 pills of about 2cm radius you have to cut or crash. Not all horses have 800kg....



    You do not need population epidemiology to see this!

    Fully agree: You can read the UK vaccination report that says the same!

  • these blood thinner drugs lessen the mortality rate by almost half regardless if they are used before or after SARS-CoV-2 infection or for that matter if they were first administered when the patient was admitted to the hospital for COVID-19 care and 3) patients in the hospital will benefit from anticoagulants reports the University of Minnesota Medical School News writer Kat Dodge.

    Bad news for Merck. Even this simple medication is better than Merck-Vectin-crap...


    New Pfizer sponsored commercial in TimesofIsrael

    Israel data: Boosters cut elderly’s risk of COVID death to 50th of unvaxxed rate
    'Dramatic figures' show over-60s who shun vaccines are not only at much greater risk of death than triple-vaxxed, but also have 65 times the chance of getting…
    www.timesofisrael.com

    Booster protection claimed to be 50x ?!


    Reality:: The boosters did cause a record number of CoV-19 infections. So all the vulnerables that got a booster are already in hospital or in ICU. Israels ICU cases just hit a new record yesterday. The backlog in serious cases is >200 ICU about 600 in critical care.

    So these figures are plain fantasy and the truth will earliest be seen in 3-4 months.


    The other bad news is that the first commercial after 2 jabs did claim a 200x protection (99.5%) . So the booster effect is 4x lower than the double jab effect.


    So boosters are plain nonsense and will further enhance your risk of autoimmune suppression.


    Disclaimer:: We here do not talk about a vaccine. We here talk about the latest cancer gene therapy technology used to treat CoV-19!

  • Tokyo reports 87 new COVID-19 cases on Oct. 4, under 100 for first time in 2021 - The Mainichi
    TOKYO -- The Tokyo Metropolitan Government announced 87 coronavirus infections in the Japanese capital on Oct. 4, marking the first time this year for
    mainichi.jp


    Tokyo cases down (one day so far) 10x. So also in Japan we see the typically vaccination boost of CoV-19 infections.

    After the main groups are now more or else vaccinated the peek flattens back to normal. In Japan the last "wave" was in sync with widespread gene therapy (vaccination). So one more proof that Drugs sell drugs....

  • India’s First Indigenously Developed COVID-19 Vaccine Summarily Rejected by the West


    India’s First Indigenously Developed COVID-19 Vaccine Summarily Rejected by the West
    The World Health Organization (WHO) rejected the emergency use authorization submission for Covaxin, the indigenously developed Indian COVID-19 vaccine
    trialsitenews.com


    The World Health Organization (WHO) rejected the emergency use authorization submission for Covaxin, the indigenously developed Indian COVID-19 vaccine developed by a partnership involving the apex research institute ICRM and the biotech venture Bharat Biotech. Actually, India’s first indigenously developed COVID-19 vaccine, the U.S. Food, and Drug Administration (FDA), already rejected a request for EUA back in the summer. In a blow to millions of Indian students and professionals that need to travel to other countries, their Covaxin vaccine won’t pass muster and must go get vaccinated again with a WHO-approved vaccine. Is Bharat Biotech and ICMR paying for an accelerated less than transparent effort?


    In a recent statement, the All-India People’s Science Network (AIPSN) noted with “sorrow and grave concern” the WHO moves to reject the Covaxin EUL request. Rather WHO requested more technical details. Considered a “serious setback” for the Indian COVID-19 vaccine as well as for the vaccine development program in India, most importantly, AIPSN reports it’s “a blow to India’s plans to distribute vaccines to other countries.”


    For example, many Indians travel worldwide for work or as a student and have already received Covaxin as a COVID-19 vaccine. Now they find it exceedingly difficult to find VISAs to travel to their destination as they must now take a WHO-approved vaccine. AIPSN declared, “This sorry state of affairs will continue as long as there is no public accountability, transparency, along with scientific rigor.”


    Because the developers of Covaxin trial data were less than transparent with their data, the application to WHO was considered “flawed.” Now AIPSN suggests “serious damage” to India’s reputation—a situation that “Besmirched the standing of Indian science and regulatory systems, which will now come under heightened international scrutiny and suspicion.” That’s because “Bharat Biotech applied to DCGI for EUA with grossly inadequate data from clinical trials inviting rejection, followed by behind-the-scenes twisting by government which resulted in the grant of EUA.” Thereafter the company did release some more Phase 3 in chunks over time. Bharat Biotech hasn’t yet published results in a peer-review journal.


    AIPSN Background

    The All-India Peoples Science Network is a network of over forty Peoples Science organizations spread all over the country. The AIPSN started its activities as a network of activist organizations involved in Science Popularization and in examining related to the interface of science with society. Since the pioneering efforts of the Bharat Jan Vigyan Jatha, in 1987, supported by the National Council for Science and Technology Communication (NCSTC), the AIPSN has emerged as a pioneer in activities related to science communication and popularization.


    The AIPSN, which had its initial thrust in the area of Science Communication, pioneered the efforts of adult literacy in the country in 1990. It nucleated the Bharat Gyan Vigyan Samiti, which went on to spearhead the Total Literacy Campaigns in Districts across the country in partnership with the Ministry of Human Resource Development (MHRD). The success of the literacy movements and the subsequent integration of several state-level BGVS organizations in the AIPSN significantly increased the reach of the AIPSN to over half the districts in the country. The literacy movements in the AIPSN have now built on the massive mobilization achieved through the total literacy programs and include activities related to continuing education, school education, women’s empowerment, co-operative credit movements, rural micro-enterprises, etc.


    WHO refusal of Emergency Use Approval for Covaxin | All India Peoples Science Network

  • Congrats: Tell this the other 400 in hospital....

    August and September were bad months for assisted living facilities in the US. 1800 deaths in august alone, I assume most if not all were vaccinated and begun receiving boosters. You might want to try to investigate this iinformation as it may help your argument.

  • Ivermectin:: How (false) negative evidence is constructed:

    https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-021-06348-5.pdf


    Onset of treatment:: time since symptom onset to the inclusion was 4 days [interquartile range 36].

    Recommended:: Days 1..3 certainly not day 6.

    Age :: The mean age was 42 years (SD ± 15.5) and the median

    Recommended for a hospitalization study look at Age >50 only

    Selection of patients >22'000 have been screened and only 500 were elected.

    This points to a huge selection bias

    Medication:: Up to 80kg 12mg over 18mg repetition rate 2x

    This is not the recommended minimal dose. minimal for 80kg is 16mg

    The repetition rate should be at least 3x or as of today 5x

    Not included. High dose V-D, zinc, doxycyline for patients with strong symptoms.


    Result 3 hospitalization among placebo 4 among Ivermectin for primary criteria..

    But:: Of all the individuals who participated in the study, 35
    (6.99%) required hospitalization at any point from
    randomization to their end of study visit. Of these, 14
    (5.60%) belonged to the ivermectin group and 21
    (8.37%) to the placebo group.


    Also PCR+:: When analyzing the RT-PCR results from nasal swabs, the Day 3 (± 1) result was negative for SARS-Cov2 in 113 patients (47.08%) in the ivermectin group and in120 patients


    Summary:: Despite trying hard, "under medication" by a factor 3 at least, missing drugs and undocumented PCR at entry the Ivermectin group at the end was performing 50% better then placebo.

    What has been communicated was a random result based on applying an illegal statistical method that only can be used if you know the rate (hospitalization) in advance.


    So rule 1: Never read the (fake) conclusion of a paper read the study.


    Rule 2: If a study uses fake medication simply throw it into the bin.

  • Of the 500 I guess they randomized into two groups, say 250 each and the percentages will be estmates of the underlying propability for a persion in that group being hospitalized. Under this assumptiion 14 and 21 could be due to random causes because basically the size of the experiment is not big enough to discover that difference. I do not find a problem with bias in this as the randomisation is proabably after the screening and hence these propabilities refer to the screend population so if you define the creterion in the scrrening you would know from what population the study says there is no signifcant difference. The critique I have is that the project is unethical, one should know that there is going to bee too few outcomes in the primiary criteria.

  • Nigerian Study Shows Ivermectin (IVM) Monotherapy as Efficacious as Hydroxychloroquine HCQ, IVM and azithromycin AZM (HIA) Combination Therapy in Treating COVID-19 Patients


    Nigerian Study Shows Ivermectin (IVM) Monotherapy as Efficacious as Hydroxychloroquine HCQ, IVM and azithromycin AZM (HIA) Combination Therapy in Treating COVID-19 Patients
    A team of clinical researchers in Nigeria presented results from a randomized controlled clinical study comparing the clinical, virological, and
    trialsitenews.com


    A team of clinical researchers in Nigeria presented results from a randomized controlled clinical study comparing the clinical, virological, and anti-inflammatory effects of ivermectin alone compared to ivermectin + HCQ + AZT triple therapy (HIA triple therapy or IVM+) in SARS-CoV-2-positive patients with COVID-19. Results from the trial showed that IVM monotherapy was equally as effective as HIA triple therapy in all inflammatory, virological and respiratory endpoints, thus substantiating the efficacy of IVM alone in treating COVID-19 infected patients.


    The single-blind, randomized control trial enrolled 62 COVID-19-positive Nigerians into two parallel groups: 30 patients received ivermectin 200 mcg/kg daily for five days, while 31 patients received HIA triple therapy. The viral cycle threshold (Ct) at pretreatment baseline and days 2, 5 14, and 21 were measured for the E- and N-genes. SPO2 (a measurement of blood oxygen level) was assessed daily, while inflammatory markers erythrocyte sedimentation rate (ESR), C-reactive protein, and D-dimer and neutrophil/lymphocyte ratios (NLRs) were assessed at baseline and day 7. Clinical status was self-assessed daily on a Likert scale.


    There was no significant treatment difference between IVM monotherapy and HIA triple therapy in any of the clinical, virological, inflammatory, and respiratory (SPO2%) comparative assessments. The data indicate that a combination of AZT + HCQ did not confer any additive benefit to IVM treating SARS-Cov-2, suggesting that AZT + HCQ may be a redundant adjuvant in COVID-19 therapy in Nigerians and elsewhere.


    The clinical research team included Olufemi Emmanuel Babalola of Bingham University, Yahaya Ndanusa from the Al-Umma Foundation, Ajayi Adesuyi of Baylor College, Onimisi John Ogedengbe and Yunusa Thairu, both from the University of Abuja and Omede Ogu of the Federal Ministry of Health, Abuja.


    A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria
    Research Square is a preprint platform that makes research communication faster, fairer, and more useful.
    www.researchsquare.com

  • University of WI-Madison & Public Health Study Indicates Vaccinated People May Spread Delta-based SARS-CoV-2 as Much as the Unvaccinated


    University of WI-Madison & Public Health Study Indicates Vaccinated People May Spread Delta-based SARS-CoV-2 as Much as the Unvaccinated
    A team of University of Wisconsin-Madison (UWM) and county public health researchers recently uploaded the results of a study to the preprint server
    trialsitenews.com




    A team of University of Wisconsin-Madison (UWM) and county public health researchers recently uploaded the results of a study to the preprint server medXriv where they investigate the SARS-CoV-2 Delta variant viral load in vaccinated and unvaccinated people. Collecting and analyzing samples of PCR threshold cycle (Ct) data from one major contact laboratory in Wisconsin, the study revealed that both vaccinated and unvaccinated individuals have similar viral loads in nasal swabs during the Delta variant COVID-19 surge. While the White House, supported by chief medical advisor Dr. Anthony Fauci, declared that the current pandemic is of the “unvaccinated,” the data across multiple sources and studies depict a very different reality. TrialSite reported on outputs from a study of Medicare data (Project Salus) indicating mass infection occurring among vaccinated people. Vaccinated people experience less hospitalization and death; however, the eradication of COVID-19 via vaccination may need a rethink.


    The findings from this large team of public health-focused scientists align with other studies indicating scenarios demonstrating that vaccinated people can still have high viral loads and transmit the disease to others. Studies referred to by the Wisconsin group include one in England and another in Singapore.


    The Study

    Led by corresponding author and public health professional Katarina Grande, a study was conducted involving the analysis of 719 individual specimens between June 29th, 2021, and July 31st, 2021—at the onset of the Delta variant-based surge. These specimens were taken from the Wisconsin Immunization Registry and Wisconsin Electronic Disease Surveillance System. Delta was the dominant strain of COVID-19 at the time, representing 69% of all Wisconsin-based sequences in GISAID starting June 27th and 95% of all samples by July 24th.


    The team was able to secure, review, and analyze the viral genome-based sequences of 122 samples. A vast majority of these samples (110 out of 122 or 90%) belonged to the Delta variant.


    The study cohorts were segmented by vaccinated and unvaccinated for this study. The study defined a vaccinated person as one who received a final dose at least two weeks before testing positive. Of the 719 individuals involved, the authors were able to obtain 293 vaccinated and 29 unvaccinated statuses from the following sources:


    ∙ Wisconsin Immunization Registry


    ∙ Wisconsin Electronic Disease Surveillance System


    The remaining data originated from self-reported vaccination information totaling 18 vaccinated and 397 unvaccinated. The researchers then analyzed both fully vaccinated and unvaccinated samples during the time of testing.


    Findings

    The authors “Detected no significant differences in Ct values by vaccination status.” For example, the authors wrote, “212 of 311 (68%) of individuals with infection despite full vaccination had extremely low Ct values <25, consistent with high viral loads.”


    The authors point out that SARS-CoV-2 infection isn’t assured with any particular Ct value; however, a body of research does indicate that “infectious SARS-CoV-2 can frequently be recovered from specimens with Ct values of 25-30 or lower. This research team sought to better qualify whether high viral loads suggest infectious SARS-CoV-2 by culturing the virus from a subset of 55 specimens with Ct values <25. The authors managed to isolate infectious SARS-CoV-2 via this method from 14 of 16 specimens (88%) from unvaccinated people and 37 of 39 specimens (95%) from vaccinated people indicating “that Ct >25 is frequently associated with the capacity to shed infectious SARS-CoV-2 even in fully vaccinated persons.”


    The researchers further analyzed the data and explored symptom status data in 516 of the 719 individuals investigated, allowing them to further evaluate Ct values in test-positive specimens based on categories including vaccination and symptom status. They found that “For symptomatic cases, there was no significant difference in the time elapsed between symptom onset and testing for vaccinated vs. unvaccinated individuals.”


    Moreover, “Full vaccination did not affect Ct values observed in infected individuals, either with or without symptoms” during the testing period. This hammered home the overall hypothesis that those individuals with known symptom status (252 of 276 of the individuals) who were not fully vaccinated (91%) still reported symptoms during the testing period. Meanwhile, 228 out of 240 people fully vaccinated (95%) reported symptoms. In other tests, the study team found that asymptomatic vaccinated individuals could also have high viral loads, thus becoming contagious as well.


    Limitations

    The study authors reported three primary limitations, including 1) only one specimen from most of the individuals limited the ability to “know the trajectory of viral loads at the time of testing; 2) possible differences between “vaccinated and unvaccinated persons seeking testing that bias our results, and 3) inherent variability in PCR Ct values because of specimen variability that’s subject to several factors from “collection technique and other variables outside of our control.”


    Conclusion

    TrialSite shares that this study has yet to be peer-reviewed and should not be cited with authority for evidence until that milestone is achieved. The data is of interest, however, and fits into an emerging observable pattern.


    Corresponding Author

    Katarina M. Grande, MPH, Public Health Madison & Dane County, Madison, WI

  • Nigerian Study Shows Ivermectin (IVM) Monotherapy as Efficacious as Hydroxychloroquine HCQ, IVM and azithromycin AZM (HIA) Combination Therapy in Treating COVID-19 Patients

    The role of azithromycin (doxycycline) is to act as an antibody to the spike. This reduces the amount of Ivermectin that also acts as very strong spike antibody and frees more Ivermectin for the intracellular action.

    HCQ and Ivermectin have the same antiviral effect but HCQ has no antibody effect! So the outcome is not a big surprise as the main action comes from Ivermectin!

  • About 70% in the US are vaccinated. Of the remaining, about half have natural immunity, so that leaves about 15% without anti-bodies.

    56% are fully vaccinated according to various sources. I do not think 20% have natural immunity. Many people who have natural immunity have suffered severe breakthrough cases. It is much safer for them to get a vaccination in addition to their natural (acquired) immunity.

    In otherwords, we are down to the hardest people, the hardcore, to convince, persuade or coerce to take the jab. They each have their reason not to get vaccinated that they obviously feel strongly about, so these scare tactics will probably have little success in making them change their minds.

    They are ~60% of the population in many rural areas of Georgia and elsewhere. They are swamping the hospitals. 2,000 a day are dying for no reason. Many are now young, so this is similar to the casualty rate of WWII. Hundreds of thousands more will die if nothing is done.

    Leave them alone I say. They are only a threat to themselves, not us.

    As noted above, they are a threat to everyone because they may produce more dangerous variants. Also because they might infect others, such as me. I will probably not die but a breakthrough case can be very bad. It can result in long-haul damage.


    They also harm me by restricting what I can do, and where I can go. I resent that.


    Also, this is costing all of us tremendous sums of money. That is also harm. Most of the people in rural Georgia are poor and they cannot pay for treatment. Even if they are billed they will never pay hundreds of thousands of dollars. The insurance companies and the government should tell all unvaccinated people there will be a $5,000 deductible. Many of them would be quick to get vaccinated.

  • The information blackout beginning

    Not sure what you mean, but I welcome anyone blacking out the antivaxxer Death Cult. Facebook and other privately owned websites should have blocked them out months ago. They have no obligation to carry antivaxxer propaganda any more than they have an obligation to publish child pornography or snuff films.

  • If that had been a vaccinated patient in the hospital, rather than someone who had taken Ivermectin, Jed would have been quick to point out that despite her difficulties at least she is talking, and she might otherwise have been dead!

    Vaccinated patients are about 20 to 100 times less likely to end up in the ICU (depending on their age and comorbidities). Taking ivermectin does nothing to prevent or cure COVID. You might as well take jelly beans.